Drugs Recalls

Failed Dissolution Specifications: Pfizer Inc. (Pfizer) is recalling PREMPRO (conjugated estrogens/medroxyprogesterone acetate tablets) because certain lots for this product may not meet the specification for conjugated estrogens dissolution.

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Lack of Assurance of Sterility: Specific lot numbers of these products have been identified for potential administration port leakage. The potential for leakage is the result of a manufacturing issue which occurred during the sealing of the closure assembly at the administration port.

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Lack of Assurance of Sterility: Specific lot numbers of these products have been identified for potential administration port leakage. The potential for leakage is the result of a manufacturing issue which occurred during the sealing of the closure assembly at the administration port.